141 related articles for article (PubMed ID: 34953891)
21. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
23. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
24. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
25. Diphenhydramine induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling and retards B16-F10 melanoma growth in vivo.
Or CR; Su HL; Lee WC; Yang SY; Ho C; Chang CC
Oncol Rep; 2016 Dec; 36(6):3465-3471. PubMed ID: 27779705
[TBL] [Abstract][Full Text] [Related]
26. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
[TBL] [Abstract][Full Text] [Related]
27. Oncostatin M-dependent Mcl-1 induction mediated by JAK1/2-STAT1/3 and CREB contributes to bioenergetic improvements and protective effects against mitochondrial dysfunction in cortical neurons.
Chang SH; Hwang CS; Yin JH; Chen SD; Yang DI
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2306-25. PubMed ID: 25986861
[TBL] [Abstract][Full Text] [Related]
28. Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.
Hu L; Wu H; Li B; Song D; Yang G; Chen G; Xie B; Xu Z; Zhang Y; Yu D; Hou J; Xiao W; Sun X; Chang G; Zhang Y; Gao L; Dai B; Tao Y; Shi J; Zhu W
Acta Biochim Biophys Sin (Shanghai); 2017 May; 49(5):420-427. PubMed ID: 28338993
[TBL] [Abstract][Full Text] [Related]
29. Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.
Gao M; Li B; Sun X; Zhou Y; Wang Y; Tompkins VS; Xu Z; Indima N; Wang H; Xiao W; Gao L; Chen G; Wu H; Wu X; Kong Y; Xie B; Zhang Y; Chang G; Hu L; Yang G; Dai B; Tao Y; Zhu W; Shi J
Theranostics; 2017; 7(15):3690-3699. PubMed ID: 29109769
[TBL] [Abstract][Full Text] [Related]
30. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells.
Zhang HY; Zhang Q; Zhang X; Yu C; Huo X; Cheng E; Wang DH; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G454-60. PubMed ID: 21148399
[TBL] [Abstract][Full Text] [Related]
31. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
32. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
33. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
Nelson EA; Walker SR; Kepich A; Gashin LB; Hideshima T; Ikeda H; Chauhan D; Anderson KC; Frank DA
Blood; 2008 Dec; 112(13):5095-102. PubMed ID: 18824601
[TBL] [Abstract][Full Text] [Related]
34. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
[TBL] [Abstract][Full Text] [Related]
35. Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells.
Lee JH; Kim C; Lee J; Um JY; Sethi G; Ahn KS
Phytomedicine; 2019 Mar; 55():282-292. PubMed ID: 30668440
[TBL] [Abstract][Full Text] [Related]
36. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ
Hepatology; 2005 Dec; 42(6):1329-38. PubMed ID: 16317687
[TBL] [Abstract][Full Text] [Related]
38. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
Dimberg LY; Dimberg A; Ivarsson K; Fryknäs M; Rickardson L; Tobin G; Ekman S; Larsson R; Gullberg U; Nilsson K; Öberg F; Wiklund HJ
BMC Cancer; 2012 Jul; 12():318. PubMed ID: 22838736
[TBL] [Abstract][Full Text] [Related]
39. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
40. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
